Cargando…
Therapeutic ISCOMATRIX™ adjuvant vaccine elicits effective anti-tumor immunity in the TRAMP-C1 mouse model of prostate cancer
Cancer vaccine development has proven challenging with the exception of some virally induced cancers for which prophylactic vaccines exist. Currently, there is only one FDA approved vaccine for the treatment of prostate cancer and as such prostate cancer continues to present a significant unmet medi...
Autores principales: | Barr, Adele M., Silva, Anabel, Prato, Sandro, Belz, Gabrielle T., Maraskovsky, Eugene, Baz Morelli, Adriana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7223769/ https://www.ncbi.nlm.nih.gov/pubmed/32388678 http://dx.doi.org/10.1007/s00262-020-02597-6 |
Ejemplares similares
-
ISCOMATRIX vaccines mediate CD8(+) T-cell cross-priming by a MyD88-dependent signaling pathway
por: Wilson, Nicholas S, et al.
Publicado: (2012) -
The CD8(+) T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIX(TM) Adjuvant
por: Manfredi, Francesco, et al.
Publicado: (2016) -
Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma
por: Cebon, Jonathan S, et al.
Publicado: (2020) -
Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability
por: Bigaeva, Emilia, et al.
Publicado: (2016) -
MRI to assess chemoprevention in transgenic adenocarcinoma of mouse prostate (TRAMP)
por: Arbab, Ali S, et al.
Publicado: (2011)